SCHEMBL18307351

SCHEMBL18307351

CC(F)CN1CCNCC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
CHRM5 P08912 1/20 0.41
CHRM3 P20309 1/20 0.41
IDO1 P14902 1/20 0.36
POLB P06746 1/20 0.35
CXCR4 P61073 2/20 0.34
SLC6A2 P23975 2/20 0.34
RAD52 P43351 1/20 0.34
SIGMAR1 Q99720 2/20 0.33
PADI1 Q9ULC6 1/20 0.33
PADI4 Q9UM07 1/20 0.33
LMNA P02545 1/20 0.32
ALDH1A1 P00352 1/20 0.32
BAX Q07812 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208440 0.80 SMN1; SMN2 (0.50) SMN1; SMN2CHRM5CHRM3IDO1POLB
SCHEMBL6921848 0.80 SMN1; SMN2 (0.50) SMN1; SMN2CHRM5CHRM3IDO1POLB
SCHEMBL1993991 0.80 SMN1; SMN2 (0.41) SMN1; SMN2CHRM5CHRM3POLBCXCR4
SCHEMBL27349170 0.80 TSHR (0.44) SMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL2326262 0.78 SMN1; SMN2 (0.44) SMN1; SMN2CHRM5CHRM3POLBCXCR4
Ammonia Solution, Strong SCHEMBL1308109 0.78 SMN1; SMN2 (0.48) SMN1; SMN2CHRM5CHRM3IDO1POLB
Hydrochloric Acid SCHEMBL6619286 0.78 SMN1; SMN2 (0.53) SMN1; SMN2CHRM5CHRM3POLBCXCR4
Hydrochloric Acid SCHEMBL7515490 0.78 SMN1; SMN2 (0.53) SMN1; SMN2CHRM5CHRM3POLBCXCR4
Hydrochloric Acid SCHEMBL7417896 0.78 SMN1; SMN2 (0.44) SMN1; SMN2CHRM5CHRM3POLBCXCR4
SCHEMBL14498527 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4618977-A1 LRRK2 INHIBITORS AND USES THEREOF Neuron23, Inc. (US) 2025-09-24 EP disclosed
US-20240208972-A1 LRRK2 INHIBITORS AND USES THEREOF NEURON23, INC. 2024-06-27 US disclosed
WO-2024108116-A1 LRRK2 INHIBITORS AND USES THEREOF NEURON23, INC. (US) 2024-05-23 WO disclosed
US-20230066771-A1 NUCLEAR RECEPTOR MODULATORS ABBVIE INC (US) 2023-03-02 US disclosed
US-20210130293-A1 NUCLEAR RECEPTOR MODULATORS ABBVIE INC (US) 2021-05-06 US disclosed
EP-3636643-A1 NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES AbbVie Inc. (US) 2020-04-15 EP disclosed
US-20190055196-A1 NUCLEAR RECEPTOR MODULATORS ABBVIE INC (US) 2019-02-21 US disclosed
CN-107820494-A Nuclear receptor modulators 艾伯维公司 2018-03-20 CN disclosed
WO-2017161344-A1 COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES THE REGANTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-09-21 WO disclosed
US-20160362370-A1 NUCLEAR RECEPTOR MODULATORS ABBVIE INC. (US) 2016-12-15 US disclosed
WO-2016200851-A1 NUCLEAR RECEPTOR MODULATORS ABBVIE INC. (US) 2016-12-15 WO disclosed
US-20160362370-A1 NUCLEAR RECEPTOR MODULATORS ABBVIE INC. (US) 2016-12-15 US disclosed
WO-2016198908-A1 ROR NUCLEAR RECEPTOR MODULATORS ABBVIE INC. (US) 2016-12-15 WO disclosed
CN-103313982-B Phenyl-isoxazole derivatives and process for the preparation thereof IL-YANG PHARM. CO.,LTD. (KR) 2016-02-03 CN disclosed
CN-103313982-A Phenyl-isoxazole derivatives and process for the preparation thereof IL YANG PHARM CO LTD 2013-09-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362370-A1 NUCLEAR RECEPTOR MODULATORS NR1I2, NR1H2, NR5A2 SMN1; SMN2 4231/4885CHRM5 795/4885CHRM3 648/4885
US-20210130293-A1 NUCLEAR RECEPTOR MODULATORS NR1I2, NR1H2, NR5A2 SMN1; SMN2 4231/4885CHRM5 795/4885CHRM3 648/4885
US-20240208972-A1 LRRK2 INHIBITORS AND USES THEREOF LRRK2, PINK1, PARK7 SMN1; SMN2 778/4885CHRM5 4694/4885CHRM3 4715/4885
US-20230066771-A1 NUCLEAR RECEPTOR MODULATORS NR1I2, NR1H2, NR5A2 SMN1; SMN2 4231/4885CHRM5 795/4885CHRM3 648/4885
US-20190055196-A1 NUCLEAR RECEPTOR MODULATORS NR1I2, NR1H2, NR5A2 SMN1; SMN2 4231/4885CHRM5 795/4885CHRM3 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.